Paxil CR: Paxil by any other name…
The Carlat Psychiatry Report, Volume 1, Number 1, January 2003
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
The latest member of the “controlled-release club” is GlaxoSmithKline, with its Paxil CR. While cynics may believe that CR launches are simply efforts to prolong patent-lives and therefore profits, the reality is that CR formulations are generally better tolerated and easier to dose.